---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-006094"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:49:59.715871+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals completes IPO of 1M shares at $7.00, raising $7M gross

## Summary
- Priced 1,000,000 shares at $7.00; gross proceeds $7M. Shares began trading on Nasdaq Feb 9 under TELO.
- Underwriters granted 45-day option to purchase up to 150,000 additional shares at IPO price.
- Representative's warrants issued to Kingswood for 50,000 shares at $7.00, exercisable after 6-month lock.
- Kingswood Investments acted as sole book-running manager; underwriting discount 7% of gross proceeds.
- Proceeds to fund development of Telomir-1, a pre-clinical small molecule for age reversal.

## SEC filing metadata
- accession: 0001493152-24-006094
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315224006094/0001493152-24-006094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315224006094/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-006094
- JSON: https://secwatch.observer/filing/0001493152-24-006094.json
- Plain text: https://secwatch.observer/filing/0001493152-24-006094.txt

## Key facts
- Material Agreements
  Telomir Pharmaceuticals, Inc. entered into Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC valued at $7,000,000 (effective 2024-02-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Kingswood Investments, division of Kingswood Capital Partners, LLC
  - Value: $7,000,000
  - Effective: 2024-02-08
  source text: On February 8, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC (“Kingswood”) on behalf of itself and as representative of the underwriters named therein (the “Underwriting Agreement”), pursuant to which the Company issued and sold, in an underwritten public offering (the “Public Offering”), 1,000,000 shares of common stock, no par value (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315224006094/0001493152-24-006094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.